You are here

Generic Version of Coreg Gains Approval

PITTSBURGH, Feb. 23 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Carvedilol Tablets 3.125 mg, 6.25 mg, 12.5 mg and 25 mg. Carvedilol Tablets are the generic version of GlaxoSmithKline's Coreg Tablets, which had annual U.S. sales of approximately $1.14 billion as of December 2005.

Source: Mylan Laboratories

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs